文献速递妇科肿瘤

贝伐珠单抗一线治疗卵巢癌随机试验最终总生存分析

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
PubMed 文献 · J Clin Oncol · 2019-06-19

GOG-0218 III期随机试验最终分析显示,对III-IV期卵巢癌患者,化疗联合贝伐珠单抗(同期或同期+维持)与单纯化疗相比,总生存无显著差异;但IV期患者同期+维持组中位OS优于对照组(42.8 vs 32.6个月),BRCA1/2或HRR突变者死亡风险较低,但这些标志物不能预测贝伐珠单抗疗效。

要点

  • 贝伐珠单抗联合化疗未改善总体人群总生存。
  • BRCA1/2和HRR状态与预后相关,但不预测贝伐珠单抗疗效。

核心结论

  • 贝伐珠单抗联合化疗与单纯化疗相比,总体人群总生存无显著差异。
  • BRCA1/2和HRR检测对预后评估重要,但不能预测贝伐珠单抗活性。

研究设计与样本

  • GOG-0218为III期随机试验,纳入1873例新诊断卵巢、输卵管或原发性腹膜癌女性。
  • 患者按1:1:1随机接受6周期卡铂+紫杉醇化疗、化疗+同期贝伐珠单抗、化疗+同期及维持贝伐珠单抗。
  • 贝伐珠单抗剂量为15 mg/kg,同期用药为第2-6周期,维持用药至第22周期。

主要发现

  • 中位随访102.9个月,对照组625例,同期贝伐珠单抗组625例,同期+维持组623例。
  • 与对照组相比,同期贝伐珠单抗组死亡HR为1.06(95%CI 0.94-1.20),同期+维持组HR为0.96(95%CI 0.85-1.09)。
  • IV期患者中,同期+维持组中位OS为42.8个月,对照组为32.6个月(HR 0.75,95%CI 0.59-0.95)。
  • BRCA1/2突变者死亡HR为0.62(95%CI 0.52-0.73),非BRCA1/2 HRR突变者HR为0.65(95%CI 0.51-0.85)。
  • BRCA1/2、HRR和CD31不能预测贝伐珠单抗疗效。

关键数值与推荐

  • 纳入标准包括GOG体能状态评分0-2,无临床显著血管事件史或肠梗阻证据。
  • 共1195例血清和/或肿瘤标本进行BRCA1/2和HRR基因测序。

临床怎么用

  • 贝伐珠单抗联合化疗未显示总体生存获益,临床决策需个体化。
  • 推荐对卵巢癌患者进行BRCA1/2和HRR检测以评估预后。

局限性

  • 未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report the final, protocol-specified analysis of overall survival (OS) in GOG-0218, a phase III, randomized trial of bevacizumab in women with newly diagnosed ovarian, fallopian tube, or primary peritoneal carcinoma. METHODS: A total of 1,873 women with incompletely resected stage III to IV disease were randomly assigned 1:1:1 to six 21-day cycles of intravenous carboplatin (area under the concentration v time curve 6) and paclitaxel (175 mg/m2) versus chemotherapy plus concurrent bevacizumab (15 mg/kg, cycles 2 to 6) versus chemotherapy plus concurrent and maintenance bevacizumab (cycles 2 to 22). Inclusion criteria included a Gynecologic Oncology Group performance status of 0 to 2 and no history of clinically significant vascular events or evidence of intestinal obstruction. OS was analyzed in the intention-to-treat population. A total of 1,195 serum and/or tumor specimens were sequenced for BRCA1/2 and damaging mutations in homologous recombination repair (HRR) genes. Intratumoral microvessel density was studied using CD31 immunohistochemistry. RESULTS: Median follow-up was 102.9 months. Relative to control (n = 625), for patients receiving bevacizumab-concurrent (n = 625), the hazard ratio (HR) of death was 1.06 (95% CI, 0.94 to 1.20); for bevacizumab-concurrent plus maintenance (n = 623), the HR was 0.96 (95% CI, 0.85 to 1.09). Disease-specific survival was not improved in any arm. No survival advantage was observed after censoring patients who received bevacizumab at crossover or as second line. Median OS for stage IV bevacizumab-concurrent plus maintenance was 42.8 v 32.6 months for stage IV control (HR, 0.75; 95% CI, 0.59 to 0.95). Relative to wild type, the HR for death for BRCA1/2 mutated carcinomas was 0.62 (95% CI, 0.52 to 0.73), and for non-BRCA1/2 HRR, the HR was 0.65 (95% CI, 0.51 to 0.85). BRCA1/2, HRR, and CD31 were not predictive of bevacizumab activity. CONCLUSION: No survival differences were observed for patients who received bevacizumab compared with chemotherapy alone. Testing for BRCA1/2 mutations and homologous recombination deficiency is essential.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tewari KS, Burger RA, Enserro D, et al. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol. 2019. PMID: 31216226. doi:10.1200/JCO.19.01009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。